The intravenous solution containing nutrient-rich formulas tailored specifically for each individuals needs will then be administered through the vein over periods ranging from 15 minutes to an hour depending on what is prescribed by the technician overseeing it
Joo JH, et al
As of this writing, there is no published randomized, placebo-controlled trial specifically examining GLP-1 agonists as a treatment for BED
The following adverse effects were reported in patients receiving semaglutide injection or oral tablets across all clinical trials and at incidences higher than with placebo: nausea (11% to 44%), vomiting (5% to 24%), diarrhea (8.5% to 30%), abdominal pain (5.7% to 20%), abdominal distention (2% to 7%), constipation (3.1% to 24%), dyspepsia (0.6% to 9%), decreased appetite (6% to 9%), eructation (0.6% to 7%), flatulence (0.4% to 6%), gastroesophageal reflux disease (1.5% to 5%), gastroenteritis (4% to 6%), and gastritis (0.4% to 4%)
One dose doesnt fit all, especially if it comes from a random vendor with little evidence that each batch is tested for contaminants
